$130 Million is the total value of Bill & Melinda Gates Foundation's 9 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VIR | VIR BIOTECHNOLOGY INC | $39,461,884 | +31.1% | 1,559,142 | 0.0% | 30.41% | +27.8% | |
| IMCR | IMMUNCORE HLDGS PLCads | $32,924,996 | +21.5% | 576,923 | 0.0% | 25.37% | +18.4% | |
| BNTX | BIONTECH SEsponsored ads | $22,333,808 | +11.1% | 148,674 | 0.0% | 17.21% | +8.3% | |
| LUMIRADX LTD | $12,857,143 | -11.9% | 14,285,714 | 0.0% | 9.91% | -14.2% | ||
| CVAC | Sell | CUREVAC N V | $9,804,436 | -27.4% | 1,625,943 | -4.9% | 7.56% | -29.2% |
| EXSCIENTIAads | $8,479,545 | -35.3% | 1,590,909 | 0.0% | 6.53% | -36.9% | ||
| BFLY | BUTTERFLY NETWORK INC | $2,487,067 | -48.2% | 1,011,003 | 0.0% | 1.92% | -49.5% | |
| BCEL | Sell | ATRECA INC | $964,878 | -54.1% | 1,206,097 | -8.7% | 0.74% | -55.2% |
| AMRS | AMYRIS INC | $464,913 | -48.3% | 292,398 | 0.0% | 0.36% | -49.6% | |
| ZY | Exit | ZYMERGEN INC | $0 | – | -59,970 | -100.0% | -0.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CUREVAC N V | 12 | Q3 2023 | 58.0% |
| VIR BIOTECHNOLOGY INC | 12 | Q3 2023 | 32.0% |
| BIONTECH SE | 12 | Q3 2023 | 35.8% |
| ATRECA INC | 12 | Q3 2023 | 5.3% |
| AMYRIS INC | 12 | Q3 2023 | 1.2% |
| IMMUNCORE HLDGS PLC | 11 | Q3 2023 | 35.7% |
| BUTTERFLY NETWORK INC | 11 | Q3 2023 | 3.8% |
| LUMIRADX LTD | 8 | Q3 2023 | 18.0% |
| EXSCIENTIA | 8 | Q3 2023 | 13.3% |
| ZYMERGEN INC | 6 | Q3 2022 | 0.3% |
View Bill & Melinda Gates Foundation's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| LumiraDx Ltd | August 03, 2022 | 19,859,773 | 15.8% |
| Atreca, Inc. | February 16, 2021 | 1,396,644 | 4.7% |
| Liquidia Technologies Inc | February 12, 2020 | 119,678 | 0.5% |
| X4 Pharmaceuticals, Inc | March 15, 2019 | 120,363 | 1.8% |
| Arsanis, Inc. | February 13, 2018 | 722,179 | 5.1% |
View Bill & Melinda Gates Foundation's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| SC 13D | 2022-08-03 |
| SC 13G | 2022-07-15 |
| 13F-HR | 2022-05-13 |
View Bill & Melinda Gates Foundation's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.